Bharat Biotech is working with the World Health Organization (WHO) to obtain Emergency Use Listing (EUL) for Covaxin, its Covid-19 vaccine, the Indian vaccine manufacturer said on Tuesday, urging an end to speculation on the permission being delayed.
The company was responding to reports that said the grant of EUL could be delayed further as WHO had more technical queries regarding the inactivated whole virus vaccine.
“As a responsible manufacturer with past approvals for our other vaccines, we do not find it appropriate to speculate or comment on the regulatory approval process and its timelines,” Bharat Biotech said in a statement on Tuesday. “We are diligently working with the WHO to obtain EUL at the earliest.”
The authorisation, when it comes, will pave the way for wider recognition of Covaxin in documentation sought by many countries that have made inoculation mandatory for entry from their borders. In the past, students seeking to study abroad faced problems because Covaxin is recognised as a Covid-19 vaccine only in a few countries.
The company earlier said it had submitted all documents to the WHO for the grant of EUL.
{{/usCountry}}The company earlier said it had submitted all documents to the WHO for the grant of EUL.
{{/usCountry}}